The recent emergence of a clinically relevant “HER2-low” phenotype supported by the efficacy of trastuzumab deruxtecan in patients with HER2 1 + and 2 + breast tumors [16] only emphasizes the need for a better understanding of HER2-driven disease and the crosstalk between these pathways. This evidence concerns the gene ERBB2 and breast neoplasm.